Related Experiment Video
Updated: May 25, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
Published on: July 19, 2019
Chronic cerebrospinal venous insufficiency as a cause of multiple sclerosis: controversy and reality
Claudiu I Diaconu1, Devon Conway, Robert J Fox
1Cleveland Clinic, Mellen Center for Multiple Sclerosis Treatment and Research, 9500 Euclid Avenue, U10, Cleveland, OH, 44195, USA.
Opinion Statement:
Multiple sclerosis (MS) is a relapsing and progressive disorder of the central nervous system. It is characterized most commonly by episodes of clinical worsening, followed by clinical improvement. Pathologically, MS is associated with focal areas of myelin destruction, inflammation, and axonal transection ("demyelinating plaques") in the brain and spinal cord. Traditionally, MS has been considered an autoimmune disorder, with the primary pathophysiology arising from an errant immune system. Recent work has raised the possibility that MS is not caused primarily by an immune abnormality but may instead arise from venous anomalies affecting the jugular and/or azygos venous systems. This condition has been called chronic cerebrospinal venous insufficiency (CCSVI). It has been proposed that CCSVI may be pathogenic in MS, causing venous back pressure and iron deposition, with a secondary immune response. Some investigators have proceeded to unblinded nonrandomized angioplasty and stenting procedures in patients with CCSVI, with anecdotal reports of symptom improvement. Because of conflicting data on the presence of CCSVI and the absence of controlled trials of CCSVI intervention, the current standard of clinical care is neither to evaluate multiple sclerosis (MS) patients for CCSVI anomalies, nor to intervene with procedures to alter such anomalies. There is intense interest and ongoing work to evaluate the presence of venous anomalies in MS patients as well as in normal controls and patients with other neurologic conditions; to characterize such anomalies, if present; and to further understand whether the concept of a "backpressure" pathology is borne out by the evidence. If CCSVI is indeed a pathogenic mechanism for some subset of the MS population, this would dramatically change the focus of attention for therapeutic endeavors and monitoring for this population and would bring MS therapeutics firmly into the area of vascular intervention. On the other hand, the history of MS research contains many novel and potentially paradigm-shifting ideas that were later disproved by other investigators.
Insights
Multiple sclerosis (MS) may be linked to chronic cerebrospinal venous insufficiency (CCSVI), a condition involving venous anomalies. Further research is needed to confirm if CCSVI causes MS and if vascular interventions are effective treatments.
Area of Science:
- Neurology
- Vascular Medicine
- Immunology
Background:
- Multiple sclerosis (MS) is a central nervous system disorder characterized by myelin destruction and inflammation, traditionally viewed as autoimmune.
- Recent hypotheses suggest venous anomalies, termed chronic cerebrospinal venous insufficiency (CCSVI), may play a primary role in MS pathogenesis.
- CCSVI is proposed to cause venous back pressure and iron deposition, leading to a secondary immune response.
Purpose of the Study:
- To evaluate the potential link between chronic cerebrospinal venous insufficiency (CCSVI) and multiple sclerosis (MS).
- To investigate whether CCSVI is a primary cause of MS or a secondary phenomenon.
- To assess the implications of CCSVI for MS diagnosis and treatment.
Main Methods:
- Review of existing literature and ongoing research on CCSVI in MS patients and control groups.
- Characterization of venous anomalies in the central nervous system.
- Analysis of evidence supporting or refuting the "backpressure" pathology theory in MS.
Main Results:
- Conflicting data exists regarding the prevalence of CCSVI in MS patients.
- Anecdotal reports suggest symptom improvement after angioplasty and stenting for CCSVI.
- Controlled trials evaluating CCSVI interventions are currently lacking.
Conclusions:
- The current standard of care does not include screening for or intervening in CCSVI for MS patients due to insufficient evidence.
- Further research is critical to determine if CCSVI is a pathogenic mechanism in a subset of MS patients.
- Confirmation of CCSVI's role could shift MS therapeutics towards vascular interventions.
Related Concept Videos
Multiple Sclerosis l: Introduction
Cerebral Edema ll: Pathophysiology
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Increased Intracranial Pressure ll: Pathophysiology
Increased Intracranial Pressure l: Introduction
Secondary Spinal Cord Injury llI: Pathophysiology
